Contact
searchSearch
HMP Global

Follicular Lymphoma

News
Axi-Cel and Tisa-Cel Show Comparable Adjusted Efficacy in Relapsed or Refractory Follicular Lymphoma
10/13/2026
Rebecca Amrick
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with...
10/13/2026
First Report Managed Care
News
Mosunetuzumab Associated With Improved Survival Among Patients With Relapsed or Refractory FL
10/09/2026
Rebecca Amrick
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that...
10/09/2026
First Report Managed Care
News
Timing of Bispecific Antibody Therapy After CAR T-Cell May Affect Outcomes Among Patients With R/R FL
09/28/2026
Rebecca Amrick
Researchers found that patients with relapsed or refractory follicular lymphoma (R/R FL) achieved short but clinically significant responses to bispecific antibodies following chimeric antigen receptor (CAR) T-cell therapy, highlighting the...
Researchers found that patients with relapsed or refractory follicular lymphoma (R/R FL) achieved short but clinically significant responses to bispecific antibodies following chimeric antigen receptor (CAR) T-cell therapy, highlighting the...
Researchers found that patients...
09/28/2026
First Report Managed Care
News
Later Lines of Therapy Drive Economic Burden in Indolent Non-Hodgkin Lymphomas
09/23/2026
Rebecca Amrick
Researchers found that indolent non-Hodgkin lymphomas, specifically follicular lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma, are associated with increased health care utilization and care costs during later lines of...
Researchers found that indolent non-Hodgkin lymphomas, specifically follicular lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma, are associated with increased health care utilization and care costs during later lines of...
Researchers found that indolent...
09/23/2026
First Report Managed Care
News
Subcutaneous Mosunetuzumab Shows Durable Responses in Relapsed/Refractory Follicular Lymphoma
09/22/2026
Hannah Musick
Subcutaneous mosunetuzumab demonstrated durable responses and predominantly low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, with efficacy outcomes similar to intravenous administration.
Subcutaneous mosunetuzumab demonstrated durable responses and predominantly low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, with efficacy outcomes similar to intravenous administration.
Subcutaneous mosunetuzumab...
09/22/2026
First Report Managed Care
News
Epcoritamab Plus R2 Demonstrates Long-Term Cost-Effectiveness in Relapsed or Refractory FL
09/17/2026
Rebecca Amrick
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis...
09/17/2026
First Report Managed Care
News
Considering Time Burden Across Bispecific Antibody Treatment Approaches in Non-Hodgkin Lymphoma
09/10/2026
Rebecca Amrick
A survey of patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) found lower time burden with fixed-duration bispecific antibody regimens, highlighting patient convenience as a crucial factor...
A survey of patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) found lower time burden with fixed-duration bispecific antibody regimens, highlighting patient convenience as a crucial factor...
A survey of patients with...
09/10/2026
First Report Managed Care
News
Tafasitamab Demonstrates Improved Clinical Benefit Among Patients With Relapsed or Refractory FL
08/10/2026
Rebecca Amrick
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding...
08/10/2026
First Report Managed Care
News
Bispecific Antibodies Linked to Lower Immune Toxicity in Follicular Lymphoma and DLBCL
07/10/2026
Grace Taylor, MS, MA
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest...
07/10/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos

What's New?

News
Axi-Cel and Tisa-Cel Show Comparable Adjusted Efficacy in Relapsed or Refractory Follicular Lymphoma
10/13/2026
Rebecca Amrick
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with...
10/13/2026
First Report Managed Care
News
Mosunetuzumab Associated With Improved Survival Among Patients With Relapsed or Refractory FL
10/09/2026
Rebecca Amrick
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that...
10/09/2026
First Report Managed Care
News
Timing of Bispecific Antibody Therapy After CAR T-Cell May Affect Outcomes Among Patients With R/R FL
09/28/2026
Rebecca Amrick
Researchers found that patients with relapsed or refractory follicular lymphoma (R/R FL) achieved short but clinically significant responses to bispecific antibodies following chimeric antigen receptor (CAR) T-cell therapy, highlighting the...
Researchers found that patients with relapsed or refractory follicular lymphoma (R/R FL) achieved short but clinically significant responses to bispecific antibodies following chimeric antigen receptor (CAR) T-cell therapy, highlighting the...
Researchers found that patients...
09/28/2026
First Report Managed Care
News
Later Lines of Therapy Drive Economic Burden in Indolent Non-Hodgkin Lymphomas
09/23/2026
Rebecca Amrick
Researchers found that indolent non-Hodgkin lymphomas, specifically follicular lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma, are associated with increased health care utilization and care costs during later lines of...
Researchers found that indolent non-Hodgkin lymphomas, specifically follicular lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma, are associated with increased health care utilization and care costs during later lines of...
Researchers found that indolent...
09/23/2026
First Report Managed Care
News
Subcutaneous Mosunetuzumab Shows Durable Responses in Relapsed/Refractory Follicular Lymphoma
09/22/2026
Hannah Musick
Subcutaneous mosunetuzumab demonstrated durable responses and predominantly low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, with efficacy outcomes similar to intravenous administration.
Subcutaneous mosunetuzumab demonstrated durable responses and predominantly low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, with efficacy outcomes similar to intravenous administration.
Subcutaneous mosunetuzumab...
09/22/2026
First Report Managed Care
News
Epcoritamab Plus R2 Demonstrates Long-Term Cost-Effectiveness in Relapsed or Refractory FL
09/17/2026
Rebecca Amrick
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis...
09/17/2026
First Report Managed Care
News
Considering Time Burden Across Bispecific Antibody Treatment Approaches in Non-Hodgkin Lymphoma
09/10/2026
Rebecca Amrick
A survey of patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) found lower time burden with fixed-duration bispecific antibody regimens, highlighting patient convenience as a crucial factor...
A survey of patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) found lower time burden with fixed-duration bispecific antibody regimens, highlighting patient convenience as a crucial factor...
A survey of patients with...
09/10/2026
First Report Managed Care
News
Tafasitamab Demonstrates Improved Clinical Benefit Among Patients With Relapsed or Refractory FL
08/10/2026
Rebecca Amrick
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding...
08/10/2026
First Report Managed Care
News
Bispecific Antibodies Linked to Lower Immune Toxicity in Follicular Lymphoma and DLBCL
07/10/2026
Grace Taylor, MS, MA
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest...
07/10/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use